**Abstract**

**Background:** Differences in symptom trajectories of behavioral and psychological symptoms with dementia (BPSD) between placebo and active drug responders have not been investigated. Additionally, ideal criteria for screening of potential placebo responders in a placebo lead-in phase in clinical trials for BPSD remain unknown.

**Methods:** The data of 371 patients with Alzheimer disease (DSM-IV) in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness for Alzheimer disease (The CATIE-AD) were analyzed. The patients were randomly assigned to treatment with olanzapine, quetiapine, risperidone, or placebo in a double-blind condition. Trajectories of Brief Psychiatric Rating Scale (BPRS) total scores were compared between placebo and active drug responders (i.e. those who achieved a ≥25% BPRS total score reduction). Prediction performance of binary classification in improvement at week 2 for placebo response at week 8 was examined; sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the consecutive cut-off points in increments of 5% between 5% and 25% in the BPRS total score reduction at week 2 were calculated.

**Results:** There were no significantly differences in symptom trajectories between placebo and drug groups. The cut-off of 10% at week 2 presented with the highest precision of 0.66 with sensitivity, NPV, specificity, and PPV of 0.53, 0.65, 0.77, and 0.68, respectively.

**Conclusion:** Symptom trajectories of BPSD in responders follow a similar pattern irrespective of treatment modalities. The 10% cut-off at week 2 seems robust for the prediction of subsequent placebo response at week 8, which may need to be considered in future clinical trials to reduce failure trials for BPSD.
